Translating Stem Cells From Laboratory to Clinic - Ontario-area scientists discuss approaches to development of stem-cell therapies. - BioPharm International

ADVERTISEMENT

Translating Stem Cells From Laboratory to Clinic
Ontario-area scientists discuss approaches to development of stem-cell therapies.


BioPharm International
Volume 26, Issue 4, pp. 40-45


Photo courtesy of the Bhatia Laboratory, McMaster Stem Cell and Cancer Research Institute (SCC-RI)
The creation of therapies using stem cells is still in early stages, with only two such products approved in North America. HEMACORD, a cell therapy derived from hematopoietic stem cells, was approved by FDA in November 2011, and Prochymal, a stem-cell treatment for treatment of host versus graft disease in children, was approved by Health Canada in May 2012. The pipeline, however, is robust: According to a 2013 report from the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 69 cell-therapy products in clinical development in the US, indicating a high level of interest in this class of therapeutics (1).

THE ONTARIO STEM-CELL CLUSTER

The development of stem-cell therapeutics is fueled by an active research effort, with a particularly dense concentration of resources in Ontario, Canada. According to the Ontario Ministry of Research and Innovation, Ontario boasts one of the largest population of stem-cell researchers in North America. The Ontario Stem Cell Initiative (OSCI) is a network of more than 85 stem-cell and regenerative medicine research programs in Ontario, representing scientists from McMaster University, Ottawa Hospital Research Institute, University of Toronto, and University of Western Ontario. The Cancer Stem Cell Consortium, which leverages international collaborations, the Stem Cell Network, and the McEwen Centre for Regenerative Medicine also function to promote collaboration among the area's stem-cell researchers. According to Jason Field, executive director of Life Sciences Ontario, "What really sets us [Ontario-area researchers] apart is our openness to collaborations. Ontario leads many provincial, national and international research collaborations that have furthered our scientific understanding in several research areas, not the least of which is stem cells and regenerative medicine."

The research effort is carried out with an eye toward commercialization. Says Field, "Ontario recognizes the need to turn our world-class research into commercialized technologies and companies that can generate jobs and other socioeconomic benefits. To that end, the province has created the ONE (Ontario Network of Excellence) —a collaborative network of organizations across the province dedicated to assisting innovators, researchers and entrepreneurs commercialize ideas. Included in the ONE are leading accelerators like MaRS Innovation and the Ontario Centres of Excellence."

Toronto is home to the Centre for Commercialization of Regenerative Medicine (CCRM), a not-for-profit organization that focuses on the development of technologies that can accelerate the commercialization of stem cell- and biomaterials-based products and therapies. "We're very focused on cell manufacturing as one of our major pillars. CCRM is an interesting model to consider, because it tries to bring industry and academia together to solve fundamental problems, ones not necessarily centered around someone's IP but more on problems that are holding back industry," says Peter Zandstra, chief scientific officer at CCRM.

Following is a discussion with Ontario life-sciences researchers about the utility of different classes of stem cells for regenerative medicine, as well as discussion of delivery strategies, manufacturing considerations, amd the obstacles in commercialization when developing stem cells as therapeutics.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA Releases REMS Report
September 25, 2014
NIH Funds Tissue Chip for Drug Screening
September 25, 2014
UPS' Pain in the Supply Chain Results
September 23, 2014
Author Guidelines
Source: BioPharm International,
Click here